A-dmDT390-bisFv(UCHT1)

BIOLOGICAL3 trials

Sponsors

Angimmune LLC, Virogen Biotechnology Inc.

Conditions

Cutaneous T-cell Lymphoma (CTCL)Mycosis FungoidesSezary SyndromeStage IV MelanomaT-cell LeukemiaT-cell Lymphomas

Phase 1

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Angimmune LLCStage IV Melanoma

Start: 2017-01-31End: 2018-06-30Target: 63Updated: 2016-12-13

Phase 2

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

CompletedNCT00611208

Angimmune LLCCutaneous T-cell Lymphoma (CTCL), Mycosis Fungoides, Sezary Syndrome +2

Start: 2008-01-31End: 2016-11-30Updated: 2016-11-29

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides

WithdrawnNCT02943642

Virogen Biotechnology Inc.Mycosis Fungoides

Start: 2026-05-01End: 2026-05-13Updated: 2026-05-18

Related Papers

Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma

Haematologica2015-03-2052 citations